PTEN、STAT3和CyclinD1蛋白在宫颈癌中的表达及意义

目的:检测PTEN、STAT3和CyclinD1蛋白在宫颈癌组织中的表达。方法:收集2009年1月～2011年1月经手术治疗的宫颈癌手术切除标本85例,所选病例按照TNM分期分为Ⅰ、Ⅱ、Ⅲ期,另取因子宫肌瘤而行子宫切除的正常宫颈上皮组织作为对照组;免疫组化法检测宫颈组织中PTEN、STAT3和CyclinD1蛋白的表达。结果:PTEN蛋白在宫颈癌组织中的阳性率为42.4%,明显低于正常对照组的95.0%(P<0.01);而STAT3和CyclinD1蛋白在癌组织中的阳性率分别为71.8%和83.5%,明显高于正常宫颈组织的15.0%和25.0%(P<0.01)。在3个临床分期中,PTEN、STAT3和CyclinD1蛋白的表达率均存在统计学差异(P<0.01),PTEN蛋白的表达量会随着临床分期的增加而减少,但STAT3和CyclinD1蛋白随着临床分期的增加其表达率也相应升高。结论:PTEN蛋白的表达降低和STAT3、CyclinD1蛋白的表达增加在宫颈癌的发生发展中起到一定的作用,可以用于肿瘤良、恶性的鉴别诊断、病理分级以及预后判断等方面。

Expressions and significances of PTEN,STAT3,and CyclinD1 in cervical cancer

Objective:To detect the expressions of PTEN,STAT3,and CyclinD1 in cervical cancer tissue. Methods:Eighty-five cervical cancer samples after surgical therapy from January 2009 to January 2011 were collected,then they were divided into stage Ⅰ,stage Ⅱ,and stage Ⅲ according to TNM staging;normal cervical epithelial tissue samples after uterine resection because of hysteromyoma were selected as control group.Immunohistochemical method was used to detect the expressions of PTEN,STAT3,and CyclinD1. Results:The positive expression rate of PTEN in cervical cancer tissue was 42.4%,which was significantly lower than that in normal control group(95.0%)(P<0.01);the positive expression rates of STAT3 and CyclinD1 in cervical cancer tissue were 71.8% and 83.5%,respectively,which were significantly higher than those in normal cervical tissue(15.0% and 25.0%,respectively)(P<0.01).There was significant difference in the expression rates of PTEN,STAT3,and CyclinD1 among the cervical cancer samples of stage Ⅰ,stage Ⅱ,and stage Ⅲ(P<0.01),the expression level of PTEN decreased with the increase of clinical stage,but the expression rates of STAT3 and CyclinD1 increased with the increase of clinical stage. Conclusion:The down-regulation of PTEN and up-regulation of STAT3 and CyclinD1 play important roles in the occurrence and development of cervical cancer,which can be used for differential diagnosis,pathological grades,and predicting prognosis of cervical tumors.